US20060198846A1 - Combinations for the treatment of diseases involving angiogenesis - Google Patents
Combinations for the treatment of diseases involving angiogenesis Download PDFInfo
- Publication number
- US20060198846A1 US20060198846A1 US11/416,283 US41628306A US2006198846A1 US 20060198846 A1 US20060198846 A1 US 20060198846A1 US 41628306 A US41628306 A US 41628306A US 2006198846 A1 US2006198846 A1 US 2006198846A1
- Authority
- US
- United States
- Prior art keywords
- nitric oxide
- arginine
- inhibitor
- derivative
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques.
- Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy. In all these diseases reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect.
- Certain chemical compounds have been shown to have vascular damaging activity against the newly formed endothelium of solid tumours.
- These agents include, for example, combretastatin A4 phosphate (Dark et al., Cancer Research 57, 1829-1834, 1997), combretastain analogues (for example those described in J Med Chem 41, 3022-32,1998 by Ohsumi et al.), the flavone acetic acids, for example 5,6-dimethylxanthenone acetic acid (Zwi, Pathology, 26, 161-9, 1994), colchicine (Baguley et al. Eur J Cancer 27, 482-7, 1991).
- combretastatin A4 phosphate Dark et al., Cancer Research 57, 1829-1834, 1997)
- combretastain analogues for example those described in J Med Chem 41, 3022-32,1998 by Ohsumi et al.
- tumours relatively resistant to vascular damaging agents is their ability to produce large amounts of nitric oxide.
- the role of nitric oxide in tumour growth is unclear and there have been reports of both tumour-stimulating and tumour-inhibiting effects (Chinje and Stratford, Essays Biochem. 32, 61-72, 1997). It has been suggested that the antitumour effects of 5,6-dimethylxanthenone acetic acid are mediated in part by nitric oxide production (Thompsen et al. Cancer Chemother Pharmacol. 31, 151-5, 1992).
- WO-A 9509621 and Br. J Cancer (1999), 77(3), 426-433 disclose combinations of cytokine releasing anticancer agents (TNF-releasing agents). These relate to ameliorating the effects of pro-inflammatory cytokines. There is no suggestion of synergistic activity from a combination of a vascular damaging agent (many of which have no pro-inflammatory activity) and an NO inhibitor.
- vascular damaging agents can be improved by combining the treatment with inhibitors of the formation or action of nitric oxide in a mammalian system.
- vascular damaging agents can be improved by combination with inhibitors of nitric oxide synthases, the enzymes that produce nitric oxide from arginine.
- efficacy of vascular damaging agents against tumours relatively resistant to their effects is improved by treatment with a nitric oxide synthase inhibitor.
- a method of treatment for a mammal having a disease that involves active angiogenesis comprising the administration of a therapeutic or subtherapeutic amount of a vascular damaging agent together with an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the vascular damaging agent.
- the method is useful for the treatment of diseases such as cancers, especially solid tumours, psoriasis, diabetic retinopathy, macular degeneration, atherosclerosis and rheumatoid arthritis.
- the vascular damaging agent and the nitric oxide synthase inhibitor can be administered together or separately.
- the method may be used as a sole therapy or in combination with other treatments.
- compounds of the invention may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, paclitaxel and docetaxel, alkylating agents, for example cisplatin, carboplatin and cyclophosphamide, antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating agents for example adriamycin and bleomycin; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide, topotecan and irinotecan; thymidylate synthase inhibitors for example raltitrexed; biological response modifiers for example interferon; antibodies for example edrecolomab;
- the vascular damaging agent and the nitric oxide synthase inhibitor can be administered by the same route or by different routes.
- routes of administration include oral, buccal, nasal, topical, rectal and parenteral administration.
- Each component of the method, the vascular damaging agent and the nitric oxide synthase inhibitor may independently be administered in a form suitable for the intended route of administration and such forms may be prepared in a conventional manner using conventional excipients.
- the pharmaceutical compositions may take the form of tablets or capsules.
- the compounds may be conveniently delivered as a powder or in solution.
- Topical administration may be as an ointment or cream and rectal administration may be as a suppository.
- the composition may take the form of, for example, a sterile solution, suspension or emulsion.
- a sterile solution for example, a sterile solution, suspension or emulsion.
- the preferred route of administration of each component will depend on the disease being treated.
- the components may each advantageously be delivered, either together or separately, as an intravenous infusion.
- Vascular damaging agents are compounds which induce selective damage to newly formed, rather than established, vasculature. Many such compounds are known and it is considered this invention is generally applicable to such agents.
- Such agents include tubulin-binding agents, for example the combretastatins and their prodrugs, the colchinols and their prodrugs and (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine and its prodrugs, TNF-alpha inducing agents such as the xanthenone acetic acids, for example dimethylxanthenoneacetic acid, and antibodies targeted to the vasculature.
- the nitric oxide synthase inhibitor is a derivative of arginine it may be, for example, an N G -substituted L-arginine selected from N G -nitro-L-arginine and alkyl esters thereof, N G -methyl-L-arginine and N G -amino-L-arginine.
- the nitric oxide synthase inhibitor is a derivative of ornithine it may be, for example L-N6-(1-iminoethyl)-ornithine.
- the nitric oxide synthase inhibitor is a derivative of lysine it may be, for example L-N6-(1-iminoethyl)-lysine.
- nitric oxide synthase inhibitor is a derivative of citrulline it may be, for example L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline such as S-methyl-L-thiocitrulline.
- compositions for the treatment of diseases involving active angiogenesis comprises a vascular damaging agent in combination with a nitric oxide synthase inhibitor where both the vascular damaging agent and the nitric oxide synthase inhibitor are as hereinbefore defined.
- the composition may contain for example a combretastatin derivative, a colchicine derivative, a colchinol derivative, a xanthenone acetic acid derivative or a vascular targeted antibody, in combination with a nitric oxide synthase inhibitor for example a derivative of arginine, a derivative of ornithine, a derivative of lysine, a derivative of citrulline, a S-alkylthioureas or an aminoguanidine.
- a nitric oxide synthase inhibitor for example a derivative of arginine, a derivative of ornithine, a derivative of lysine, a derivative of citrulline, a S-alkylthioureas or an aminoguanidine.
- combretastatin A4 and its prodrugs for example combretastatin A4 phosphate, (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine and its prodrugs
- N-acetylcolchinol and its prodrugs for example N-acetylcolchinol-O-phosphate and 5,6-dimethylxanthenoneacetic acid.
- nitric oxide synthase inhibitors which may be present in the composition include derivatives of arginine, ornithine, lysine and citrulline, S-alkylthioureas aminoguanidines and aminopyridines.
- the nitric oxide synthase inhibitor is a derivative of arginine it may be, for example, an N G -substituted L-arginine selected from N G -nitro-L-arginine and alkyl esters thereof, N G -methyl-L-arginine and N G -amino-L-arginine.
- nitric oxide synthase inhibitor is a derivative of ornithine it may be, for example L-N6-(1-iminoethyl)-ornithine.
- nitric oxide synthase inhibitor is a derivative of lysine it may be, for example L-N6-(1-iminoethyl)-lysine.
- nitric oxide synthase inhibitor is a derivative of citrulline it may be, for example L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline such as S-methyl-L-thiocitrulline.
- the nitric oxide synthase inhibitor is an aminopyridine it may be for example 2-amino-4-methylpyridine.
- each component will be determined by the identity of each individual vascular damaging agent or nitric oxide synthase inhibitor and by the disease to be treated.
- the composition may include pharmaceutically acceptable excipients selected with regard to the intended route of administration and standard pharmaceutical practice.
- the composition may take a form suitable for oral, buccal, nasal, topical, rectal or parenteral administration and may be prepared in a conventional manner using conventional excipients.
- oral administration the composition may take the form of tablets or capsules.
- nasal administration or administration by inhalation the compounds may be conveniently delivered as a powder or in solution.
- Topical administration may be as an ointment or cream and rectal administration may be as a suppository.
- parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
- the composition may take the form of, for example, a sterile solution, suspension or emulsion.
- the dose of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the identity of the individual components, the route of administration, the form and severity of the condition and whether the compound is to be administered alone or in combination with another drug. Thus the precise dose will be determined by the administering physician and will depend on the particular vascular damaging agent and NO synthase inhibitor in the composition.
- the dose of the vascular damaging agent envisaged is, for example, in the range 10-1000 mg/m 2 body surface, preferably 20-200 mg/m 2 and that for the nitric oxide inhibitor 1-1000 mg/m 2 , preferably 5-5000 mg/m 2 .
- a unit dose form of the vascular damaging agent as, for example, a sterile solution for injection will usually contain, for example, 40-400 mg of the active ingredient.
- a unit dose form of the nitric oxide synthase inhibitor as, for example, a sterile solution for injection will usually contain, for example, 10-1000 mg of the active ingredient.
- a unit dose form of a composition containing both a vascular damaging agent and a nitric oxide synthase inhibitor as, for example, a sterile solution for injection will usually contain, for example, 40-400 mg of the vascular damaging agent and 10-1000 mg of the nitric oxide synthase inhibitor.
- composition of the invention may be administered as a sole therapy or in combination with other treatments.
- the composition may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, paclitaxel and docetaxel; alkylating agents, for example cisplatin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating agents for example adriamycin and bleomycin; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide, topotecan and irinotecan; thymidylate synthase inhibitors for example raltitrexed; biological response modifiers for example interferon; antibodies for example edrecolomab; and anti-hormones for example tamoxifen.
- Such combination treatment may involve simultaneous or sequential
- Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit J Cancer 57, 247-253, 1988).
- the fluorescent dye was dissolved in saline at 6.25 mg/ml and injected intravenously at 10 mg/kg 24 hours after intra peritoneal drug treatment.
- animals were killed and tumours excised and frozen; 10 ⁇ m sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (J Natl Cancer Inst, 4, 47-53, 1943).
- CA4P Combretastatin A4 phosphate
- L-NNA L-N G -nitroarginine
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrotherapy Devices (AREA)
Abstract
Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of said compounds and treatment employing said materials.
Description
- This invention relates to a method for treating diseases involving active angiogenesis, to compositions useful for the treatment of diseases involving angiogenesis and to the use of the compositions in the preparation of a medicament for the treatment of diseases involving active angiogenesis. In one aspect of the invention the method involves the administration to a mammal of an inhibitor of nitric oxide in combination with a compound inducing vascular damage.
- Formation of new vasculature by angiogenesis is a key pathological feature of several diseases (J Folkman, New England Journal of Medicine 333, 1757-1763, 1995). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy. In all these diseases reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect.
- Certain chemical compounds have been shown to have vascular damaging activity against the newly formed endothelium of solid tumours. These agents include, for example, combretastatin A4 phosphate (Dark et al., Cancer Research 57, 1829-1834, 1997), combretastain analogues (for example those described in J Med Chem 41, 3022-32,1998 by Ohsumi et al.), the flavone acetic acids, for example 5,6-dimethylxanthenone acetic acid (Zwi, Pathology, 26, 161-9, 1994), colchicine (Baguley et al. Eur J Cancer 27, 482-7, 1991). However some tumours are resistant to these agents.
- One characteristic of tumours relatively resistant to vascular damaging agents is their ability to produce large amounts of nitric oxide. The role of nitric oxide in tumour growth is unclear and there have been reports of both tumour-stimulating and tumour-inhibiting effects (Chinje and Stratford, Essays Biochem. 32, 61-72, 1997). It has been suggested that the antitumour effects of 5,6-dimethylxanthenone acetic acid are mediated in part by nitric oxide production (Thompsen et al. Cancer Chemother Pharmacol. 31, 151-5, 1992).
- WO-A 9509621 and Br. J Cancer (1999), 77(3), 426-433 disclose combinations of cytokine releasing anticancer agents (TNF-releasing agents). These relate to ameliorating the effects of pro-inflammatory cytokines. There is no suggestion of synergistic activity from a combination of a vascular damaging agent (many of which have no pro-inflammatory activity) and an NO inhibitor.
- We have found that the efficacy of vascular damaging agents can be improved by combining the treatment with inhibitors of the formation or action of nitric oxide in a mammalian system.
- In particular the efficacy of vascular damaging agents can be improved by combination with inhibitors of nitric oxide synthases, the enzymes that produce nitric oxide from arginine. In particular the efficacy of vascular damaging agents against tumours relatively resistant to their effects is improved by treatment with a nitric oxide synthase inhibitor.
- Accordingly in one aspect of the invention we provide a method of treatment for a mammal having a disease that involves active angiogenesis such method comprising the administration of a therapeutic or subtherapeutic amount of a vascular damaging agent together with an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the vascular damaging agent. The method is useful for the treatment of diseases such as cancers, especially solid tumours, psoriasis, diabetic retinopathy, macular degeneration, atherosclerosis and rheumatoid arthritis.
- The vascular damaging agent and the nitric oxide synthase inhibitor can be administered together or separately. The method may be used as a sole therapy or in combination with other treatments. For the treatment of solid tumours compounds of the invention may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, paclitaxel and docetaxel, alkylating agents, for example cisplatin, carboplatin and cyclophosphamide, antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating agents for example adriamycin and bleomycin; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide, topotecan and irinotecan; thymidylate synthase inhibitors for example raltitrexed; biological response modifiers for example interferon; antibodies for example edrecolomab; and anti-hormones for example tamoxifen. Such combination treatment may involve simultaneous or sequential application of the individual components of the treatment.
- The vascular damaging agent and the nitric oxide synthase inhibitor can be administered by the same route or by different routes. Such routes of administration include oral, buccal, nasal, topical, rectal and parenteral administration. Each component of the method, the vascular damaging agent and the nitric oxide synthase inhibitor may independently be administered in a form suitable for the intended route of administration and such forms may be prepared in a conventional manner using conventional excipients. For example for oral administration the pharmaceutical compositions may take the form of tablets or capsules. For nasal administration or administration by inhalation the compounds may be conveniently delivered as a powder or in solution. Topical administration may be as an ointment or cream and rectal administration may be as a suppository. For parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) the composition may take the form of, for example, a sterile solution, suspension or emulsion. The preferred route of administration of each component will depend on the disease being treated. For solid tumours the components may each advantageously be delivered, either together or separately, as an intravenous infusion.
- Vascular damaging agents are compounds which induce selective damage to newly formed, rather than established, vasculature. Many such compounds are known and it is considered this invention is generally applicable to such agents. Such agents include tubulin-binding agents, for example the combretastatins and their prodrugs, the colchinols and their prodrugs and (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine and its prodrugs, TNF-alpha inducing agents such as the xanthenone acetic acids, for example dimethylxanthenoneacetic acid, and antibodies targeted to the vasculature.
- A wide variety of compounds which inhibit the formation or action of nitric oxide in mammalian systems can be employed. Specifically nitric oxide synthase inhibitors are those compounds which inhibit any of the forms of nitric oxide synthase. Such agents include derivatives of arginine, ornithine, lysine and citrulline, S-alkylthioureas and aminoguanidines. Where the nitric oxide synthase inhibitor is a derivative of arginine it may be, for example, an NG-substituted L-arginine selected from NG-nitro-L-arginine and alkyl esters thereof, NG-methyl-L-arginine and NG-amino-L-arginine. Where the nitric oxide synthase inhibitor is a derivative of ornithine it may be, for example L-N6-(1-iminoethyl)-ornithine. Where the nitric oxide synthase inhibitor is a derivative of lysine it may be, for example L-N6-(1-iminoethyl)-lysine. Where the nitric oxide synthase inhibitor is a derivative of citrulline it may be, for example L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline such as S-methyl-L-thiocitrulline.
- In a further embodiment of the invention there is provided a composition for the treatment of diseases involving active angiogenesis. The composition of the invention comprises a vascular damaging agent in combination with a nitric oxide synthase inhibitor where both the vascular damaging agent and the nitric oxide synthase inhibitor are as hereinbefore defined.
- Thus for example the composition may contain for example a combretastatin derivative, a colchicine derivative, a colchinol derivative, a xanthenone acetic acid derivative or a vascular targeted antibody, in combination with a nitric oxide synthase inhibitor for example a derivative of arginine, a derivative of ornithine, a derivative of lysine, a derivative of citrulline, a S-alkylthioureas or an aminoguanidine.
- Particular examples of vascular damaging agents that may be present in the composition include combretastatin A4 and its prodrugs for example combretastatin A4 phosphate, (Z)-2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenylamine and its prodrugs, N-acetylcolchinol and its prodrugs for example N-acetylcolchinol-O-phosphate and 5,6-dimethylxanthenoneacetic acid.
- Particular examples of nitric oxide synthase inhibitors which may be present in the composition include derivatives of arginine, ornithine, lysine and citrulline, S-alkylthioureas aminoguanidines and aminopyridines. Where the nitric oxide synthase inhibitor is a derivative of arginine it may be, for example, an NG-substituted L-arginine selected from NG-nitro-L-arginine and alkyl esters thereof, NG-methyl-L-arginine and NG-amino-L-arginine. Where the nitric oxide synthase inhibitor is a derivative of ornithine it may be, for example L-N6-(1-iminoethyl)-ornithine. Where the nitric oxide synthase inhibitor is a derivative of lysine it may be, for example L-N6-(1-iminoethyl)-lysine. Where the nitric oxide synthase inhibitor is a derivative of citrulline it may be, for example L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline such as S-methyl-L-thiocitrulline. Where the nitric oxide synthase inhibitor is an aminopyridine it may be for example 2-amino-4-methylpyridine.
- The composition is useful for the treatment of diseases involving active angiogenesis for example solid tumours, psoriasis, diabetic retinopathy, macular degeneration, atherosclerosis and rheumatoid arthritis.
- The relative proportion of each component will be determined by the identity of each individual vascular damaging agent or nitric oxide synthase inhibitor and by the disease to be treated.
- The composition may include pharmaceutically acceptable excipients selected with regard to the intended route of administration and standard pharmaceutical practice. The composition may take a form suitable for oral, buccal, nasal, topical, rectal or parenteral administration and may be prepared in a conventional manner using conventional excipients. For example for oral administration the composition may take the form of tablets or capsules. For nasal administration or administration by inhalation the compounds may be conveniently delivered as a powder or in solution. Topical administration may be as an ointment or cream and rectal administration may be as a suppository. For parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) the composition may take the form of, for example, a sterile solution, suspension or emulsion.
- The dose of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the identity of the individual components, the route of administration, the form and severity of the condition and whether the compound is to be administered alone or in combination with another drug. Thus the precise dose will be determined by the administering physician and will depend on the particular vascular damaging agent and NO synthase inhibitor in the composition. However the dose of the vascular damaging agent envisaged is, for example, in the range 10-1000 mg/m2 body surface, preferably 20-200 mg/m2 and that for the nitric oxide inhibitor 1-1000 mg/m2, preferably 5-5000 mg/m2. A unit dose form of the vascular damaging agent as, for example, a sterile solution for injection will usually contain, for example, 40-400 mg of the active ingredient. A unit dose form of the nitric oxide synthase inhibitor as, for example, a sterile solution for injection will usually contain, for example, 10-1000 mg of the active ingredient. A unit dose form of a composition containing both a vascular damaging agent and a nitric oxide synthase inhibitor as, for example, a sterile solution for injection will usually contain, for example, 40-400 mg of the vascular damaging agent and 10-1000 mg of the nitric oxide synthase inhibitor.
- The composition of the invention may be administered as a sole therapy or in combination with other treatments. For the treatment of solid tumours the composition may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, paclitaxel and docetaxel; alkylating agents, for example cisplatin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating agents for example adriamycin and bleomycin; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide, topotecan and irinotecan; thymidylate synthase inhibitors for example raltitrexed; biological response modifiers for example interferon; antibodies for example edrecolomab; and anti-hormones for example tamoxifen. Such combination treatment may involve simultaneous or sequential application of the individual components of the treatment.
- In a further embodiment of the invention we provide the use of a compostion of the invention for the preparation of a medicament for the treatment of a disease involving active angiogenesis.
- The invention will now be illustrated by the following Examples in which biological assays are used to illustrate the invention:
- Induction of Necrosis
- Mice bearing either CaNT or SaS tumours were treated with the test compound and tumours excised after 24 h, fixed in formalin, embedded in paraffin, sectioned and stained with haematoxylin and eosin. Sections were scored based on area of necrosis as follows:
% necrosis score 0-10 1 11-20 2 21-30 3 31-40 4 41-50 5 51-60 6 61-70 7 71-80 8 81-90 9 91-100 10
Control tumours had mean scores of 2.0 (CaNT) and 1.0 (SaS). - In this assay the effect of a given dose of either a vascular damaging agent or a nitric oxide synthase inhibitor administered alone can be compared with the effect of a combination of the two agents.
TABLE 1 Enhancement of Combretastatin A4 phosphate (CA4P) activity in SaS tumours by coadministration of L-NG-nitroarginine (L-NNA) Necrosis score ± SEM Treatment (n) None 1.0 ± 0 (10) CA4P, 500 mg/kg 1.7 ± 0.7 (3) L-NNA, 10 mg/kg 2.0 ± 1 (3) CA4P, 500 mg/kg + L-NNA 10 mg/kg 9.0 ± 0 (3) -
TABLE 2 Enhancement of Combretastatin A4 phosphate (CA4P) activity in SaS tumours by coadministration of 2-amino-4-methylpyridine (AMP) Necrosis score ± SEM Treatment (n) None 1.0 ± 0 (10) CA4P, 500 mg/kg 1.7 ± 0.7 (3) AMP, 10 mg/kg 1.0 (2) CA4P, 500 mg/kg + AMP 10 mg/kg 4.5 (2) - The following experiment further demonstrates the ability of the compounds to damage tumour vasculature.
- Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit J Cancer 57, 247-253, 1988). The fluorescent dye was dissolved in saline at 6.25 mg/ml and injected intravenously at 10 mg/kg 24 hours after intra peritoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10 μm sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (J Natl Cancer Inst, 4, 47-53, 1943). All estimates were based on counting a minimum of 100 fields from sections cut at the 3 different levels.
TABLE 3 Enhancement of Combretastatin A4 phosphate (CA4P) activity in CaNT tumours by coadministration of L-NG-nitroarginine (L-NNA). Vascular Volume % ± SEM Treatment (n) None 2.35 CA4P, 25 mg/kg 1.03 ± 0.14 (4) L-NNA, 10 mg/kg 2.45 ± 0.04 (3) CA4P, 25 mg/kg + L-NNA 10 mg/kg 0.63 ± 0.25 (3)
Claims (9)
1-15. (canceled)
16. A pharmaceutical composition for the treatment of a disease involving active angiogenesis which comprises (a) a tubulin binding agent in an amount sufficient to cause damage to neovaasculature, (b) an inhibitor of the formation of nitric oxide in a mammalian system and (c) a pharmaceutically acceptable excipient.
17. A pharmaceutical composition for the damage of the formation of new vasculature by angiogenesis comprising a combination of (a) a tubulin binding agent in an amount sufficient to cause damage to neovasculature, (b) an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the tubulin binding agent and (c) a pharmaceutically acceptable excipient.
18. A composition according to claim 2 wherein the inhibitor of nitric oxide synthase is selected from a derivative of arginine, ornithine, lysine, citrulline, S-alkylthioureas and aminoguanidine.
19. A composition according to claim 4 wherein the nitric oxide synthase inhibitor is an NG-substituted L-arginine selected from N-nitro-L-arginine and alkyl esters thereof, NG-methyl-L-arginine and NG-amino-L-arginine.
20. A composition according to claim 4 wherein the derivative of ornithine is L-N6-(1iminoethyl)-ornithine.
21. A composition according to claim 4 wherein the derivative of lysine is L-N6-(1-iminoethyl)-lysine.
22. A composition according to claim 4 wherein the derivative of citrulline is selected from L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline.
23. A composition according to claim 1 wherein the composition is in the form of a kit, one part of the kit containing the tubulin binding agent and the second part of the kit the inhibitor of the formation of nitric oxide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/416,283 US20060198846A1 (en) | 1999-02-16 | 2006-05-01 | Combinations for the treatment of diseases involving angiogenesis |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9903404.3A GB9903404D0 (en) | 1999-02-16 | 1999-02-16 | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
GB9903404.3 | 1999-02-16 | ||
PCT/GB2000/000511 WO2000048591A1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
US09/890,989 US7087627B1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
US11/416,283 US20060198846A1 (en) | 1999-02-16 | 2006-05-01 | Combinations for the treatment of diseases involving angiogenesis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/890,989 Continuation US7087627B1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
PCT/GB2000/000511 Continuation WO2000048591A1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060198846A1 true US20060198846A1 (en) | 2006-09-07 |
Family
ID=10847791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/890,989 Expired - Fee Related US7087627B1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
US11/416,283 Abandoned US20060198846A1 (en) | 1999-02-16 | 2006-05-01 | Combinations for the treatment of diseases involving angiogenesis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/890,989 Expired - Fee Related US7087627B1 (en) | 1999-02-16 | 2000-02-15 | Combinations for the treatment of diseases involving angiogenesis |
Country Status (21)
Country | Link |
---|---|
US (2) | US7087627B1 (en) |
EP (1) | EP1161235B1 (en) |
JP (1) | JP4708569B2 (en) |
KR (2) | KR20010102038A (en) |
CN (1) | CN1344159B (en) |
AT (1) | ATE288264T1 (en) |
AU (1) | AU775242B2 (en) |
BR (1) | BR0008254A (en) |
CA (1) | CA2362281C (en) |
DE (1) | DE60017878T2 (en) |
DK (1) | DK1161235T3 (en) |
ES (1) | ES2237407T3 (en) |
GB (1) | GB9903404D0 (en) |
HK (1) | HK1040919B (en) |
IL (2) | IL144847A0 (en) |
MX (1) | MXPA01008245A (en) |
NO (1) | NO20013966L (en) |
NZ (1) | NZ513429A (en) |
PT (1) | PT1161235E (en) |
WO (1) | WO2000048591A1 (en) |
ZA (1) | ZA200106688B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080114021A1 (en) * | 2006-11-09 | 2008-05-15 | University Of Maryland Baltimore | Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001247459A (en) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | Combination therapy for cancer |
EE200200565A (en) | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Combination therapy with vascular adverse effects |
WO2002009700A1 (en) | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
US20050153939A1 (en) | 2003-09-10 | 2005-07-14 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts |
US6670344B2 (en) | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
JP2004517821A (en) * | 2000-10-27 | 2004-06-17 | アベンティス・ファーマ・ソシエテ・アノニム | Combinations of camptothecin and stilbene derivatives for cancer treatment |
WO2002056692A1 (en) * | 2000-12-22 | 2002-07-25 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
JP2004536847A (en) * | 2001-07-13 | 2004-12-09 | オキシジーン, インコーポレイテッド | Compositions and methods for administering tubulin binding agents for the treatment of ocular diseases |
AU2008202468B2 (en) * | 2001-07-13 | 2011-08-11 | Oxigene, Inc. | Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases |
ES2252160T3 (en) * | 2001-08-30 | 2006-05-16 | Cancer Research Technology Limited | ANTI-BANK COMBINATIONS OF DMXAA AND PACLITAXEL OR DOCETAXEL. |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
WO2008100591A2 (en) * | 2007-02-14 | 2008-08-21 | The General Hospital Corporation | Modulation of nitric oxide signaling to normalize tumor vasculature |
SI2219451T1 (en) | 2007-11-21 | 2015-02-27 | Oxigene, Inc. | Method for treating hematopoietic neoplasms |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
CA2905509A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
WO2017031157A1 (en) | 2015-08-18 | 2017-02-23 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08503940A (en) * | 1992-11-27 | 1996-04-30 | ザ ウエルカム ファウンデーション リミテッド | Enzyme inhibitors |
US5424447A (en) | 1993-07-07 | 1995-06-13 | The Medical College Of Wisconsin Research Foundation, Inc. | Heme binding compounds and use thereof |
GB9320484D0 (en) * | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
WO1996018617A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
JP2000506170A (en) | 1996-03-05 | 2000-05-23 | メデイノックス,インコーポレイテッド | Combination therapy using nitric oxide scavenger and composition useful therefor |
MY117948A (en) * | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
-
1999
- 1999-02-16 GB GBGB9903404.3A patent/GB9903404D0/en not_active Ceased
-
2000
- 2000-02-15 WO PCT/GB2000/000511 patent/WO2000048591A1/en not_active Application Discontinuation
- 2000-02-15 KR KR1020017010121A patent/KR20010102038A/en active IP Right Grant
- 2000-02-15 BR BR0008254-6A patent/BR0008254A/en not_active Application Discontinuation
- 2000-02-15 MX MXPA01008245A patent/MXPA01008245A/en active IP Right Grant
- 2000-02-15 ES ES00903832T patent/ES2237407T3/en not_active Expired - Lifetime
- 2000-02-15 PT PT00903832T patent/PT1161235E/en unknown
- 2000-02-15 DE DE60017878T patent/DE60017878T2/en not_active Expired - Fee Related
- 2000-02-15 AU AU25590/00A patent/AU775242B2/en not_active Ceased
- 2000-02-15 JP JP2000599383A patent/JP4708569B2/en not_active Expired - Fee Related
- 2000-02-15 CN CN008050961A patent/CN1344159B/en not_active Expired - Fee Related
- 2000-02-15 US US09/890,989 patent/US7087627B1/en not_active Expired - Fee Related
- 2000-02-15 DK DK00903832T patent/DK1161235T3/en active
- 2000-02-15 NZ NZ513429A patent/NZ513429A/en not_active IP Right Cessation
- 2000-02-15 CA CA002362281A patent/CA2362281C/en not_active Expired - Fee Related
- 2000-02-15 KR KR1020077004923A patent/KR20070034642A/en not_active Application Discontinuation
- 2000-02-15 AT AT00903832T patent/ATE288264T1/en not_active IP Right Cessation
- 2000-02-15 EP EP00903832A patent/EP1161235B1/en not_active Expired - Lifetime
- 2000-02-15 IL IL14484700A patent/IL144847A0/en active IP Right Grant
-
2001
- 2001-08-09 IL IL144847A patent/IL144847A/en not_active IP Right Cessation
- 2001-08-14 ZA ZA200106688A patent/ZA200106688B/en unknown
- 2001-08-15 NO NO20013966A patent/NO20013966L/en unknown
-
2002
- 2002-04-08 HK HK02102577.5A patent/HK1040919B/en not_active IP Right Cessation
-
2006
- 2006-05-01 US US11/416,283 patent/US20060198846A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080114021A1 (en) * | 2006-11-09 | 2008-05-15 | University Of Maryland Baltimore | Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent |
WO2008147445A2 (en) * | 2006-11-09 | 2008-12-04 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
WO2008147445A3 (en) * | 2006-11-09 | 2009-01-15 | Univ Maryland | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
US20110218239A1 (en) * | 2006-11-09 | 2011-09-08 | University Of Maryland Baltimore | Use of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antiviral Agent |
US8957108B2 (en) | 2006-11-09 | 2015-02-17 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antiviral agent |
Also Published As
Publication number | Publication date |
---|---|
MXPA01008245A (en) | 2002-10-23 |
HK1040919B (en) | 2005-05-13 |
JP4708569B2 (en) | 2011-06-22 |
BR0008254A (en) | 2001-11-06 |
GB9903404D0 (en) | 1999-04-07 |
KR20070034642A (en) | 2007-03-28 |
EP1161235A1 (en) | 2001-12-12 |
NZ513429A (en) | 2003-10-31 |
ZA200106688B (en) | 2002-08-14 |
DE60017878T2 (en) | 2006-01-26 |
KR20010102038A (en) | 2001-11-15 |
CN1344159A (en) | 2002-04-10 |
NO20013966L (en) | 2001-10-15 |
JP2002537251A (en) | 2002-11-05 |
EP1161235B1 (en) | 2005-02-02 |
IL144847A0 (en) | 2002-06-30 |
ATE288264T1 (en) | 2005-02-15 |
NO20013966D0 (en) | 2001-08-15 |
PT1161235E (en) | 2005-05-31 |
AU2559000A (en) | 2000-09-04 |
CA2362281C (en) | 2008-11-18 |
HK1040919A1 (en) | 2002-06-28 |
AU775242B2 (en) | 2004-07-22 |
CN1344159B (en) | 2011-09-28 |
CA2362281A1 (en) | 2000-08-24 |
WO2000048591A1 (en) | 2000-08-24 |
IL144847A (en) | 2006-10-31 |
DK1161235T3 (en) | 2005-05-09 |
ES2237407T3 (en) | 2005-08-01 |
US7087627B1 (en) | 2006-08-08 |
DE60017878D1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060198846A1 (en) | Combinations for the treatment of diseases involving angiogenesis | |
AU2001253919B2 (en) | Administration of a thiol-based chemoprotectant compound | |
AU2001253919A1 (en) | Administration of a thiol-based chemoprotectant compound | |
AU2001242581B2 (en) | Combination therapies with vascular damaging activity | |
JP2021536502A (en) | Use of amino acid-based nutrients and pharmaceutical compositions containing them | |
AU2001242581A1 (en) | Combination therapies with vascular damaging activity | |
JPH10511347A (en) | Combination chemotherapy with suramin and vinca alkaloids or estramustine | |
US20170258817A1 (en) | Fosfestrol for use in curative or palliative treatment of prostate cancer | |
JP2004526760A (en) | Toluenesulfonamide-containing antitumor composition and method for producing the same | |
CN112438942A (en) | Pharmaceutical composition containing alkalizer and its synergist and its application | |
EP1272200B1 (en) | Divided dose therapies with vascular damaging activity | |
CN112439066A (en) | Pharmaceutical composition comprising chemical ablation agent and pH adjusting agent and use thereof | |
US20230346741A1 (en) | Eriodictyol compositions and methods | |
WO2022183493A1 (en) | Application of polyphenol compound | |
US20040067255A1 (en) | Method of administering split doses of a vascular targeting agent | |
AU2003274306B2 (en) | Combination therapy with gemcitabine and ZD6126 | |
MX2013004423A (en) | Use of cysteamine and derivatives thereof to suppress tumor metastases. | |
ZA200207114B (en) | Combination therapies with vascular damaging activity. | |
ZA200208350B (en) | Administration of a thiol-based chemoprotectant compound. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANGIOGENE PHARMACEUTICALS LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DAVIS, PETER DAVID;REEL/FRAME:025354/0243 Effective date: 20011126 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |